Status:
COMPLETED
Immunoreactivity to Cetuximab in Cancer Patients
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Colorectal Cancer
Head and Neck Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
RATIONALE: Studying samples of blood in the laboratory may help doctors predict which patients will develop hypersensitivity to cetuximab. PURPOSE: This research study is looking at hypersensitivity ...
Detailed Description
OBJECTIVES: * To examine serum samples from patients with head and neck cancer or advanced colorectal cancer previously treated with cetuximab for the presence of antibodies against cetuximab. OUTLI...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of one of the following:
- Head and neck cancer
- Advanced colorectal cancer
- Previously treated with cetuximab
- Serum samples available from patients enrolled in one of the following clinical trials:
- VU-VICC-GI-0410 (colorectal cancer)
- VU-VICC-GI-0622 (colorectal cancer)
- VU-VICC-HN-0356 (head and neck cancer)
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
November 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
538 Patients enrolled
Trial Details
Trial ID
NCT00896896
Start Date
November 1 2006
End Date
October 1 2008
Last Update
April 2 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.